Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836105 · ClinicalTrials.gov registry record
CemiplimAb Survivorship Epidemiology
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 287
- Enrollment target
NCT03836105 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 287 participants.
The verdict
NCT03836105 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 287 participants
- Enrollment target
Study Summary
The objectives of the study are: * To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) cutaneous squamous cell carcinoma (CSCC) and patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) basal cell carcinoma (BCC) in real-world clinical settings * To evaluate the safety of cemiplimab based on incidence of treatment related immune-related adverse events (irAEs), infusion related reactions (IRRs), and treatment related serious adverse reactions (TSARs) in patients with advanced CSCC and patients with advanced BCC receiving cemiplimab treatment in real world clinical settings * To describe patient experience, including patient reported quality of life (QOL) and functional status, and clinician reported performance status in a real-world setting for patients with advanced CSCC and patients with advanced BCC * To describe baseline characteristics that could potentially be associated with health-related outcomes for patients with advanced CSCC and patients with advanced BCC undergoing treatment with cemiplimab * To describe patients who receive cemiplimab as treatment for CSCC or BCC in a real-world setting * To describe real-world use patterns of cemiplimab for CSCC and BCC * To investigate the long-term effects and effectiveness of cemiplimab in patients with advanced CSCC or advanced BCC * To describe the effectiveness of cemiplimab in immunosuppressed and immunocompetent patients with advanced CSCC or advanced BCC, regardless of etiology, per available data * To describe the effectiveness of cemiplimab after prior exposure to radiation therapy for CSCC per available data * To describe the effectiveness of cemiplimab as a first-line (1L) or later systemic treatment in patients with advanced CSCC, regardless of etiology, per available data * To describe the effectiveness of cemiplimab in patients with
Interventions
- DRUG cemiplimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2025-09-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03836105
The ClinicalTrials.gov registry entry for NCT03836105 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cemiplimab is the first listed.
NCT03836105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03836105 about?
NCT03836105 is a clinical study titled "CemiplimAb Survivorship Epidemiology". The objectives of the study are: * To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) cutaneous squamous cell carcinoma (CSCC) and patients with advanced (define...
What is the current status of trial NCT03836105?
This trial is currently completed. The enrollment target is 287 participants. The study started on 2019-06-27. Estimated completion is 2025-09-29.
What interventions are being tested in trial NCT03836105?
The interventions under investigation include: cemiplimab (DRUG).
Who is sponsoring clinical trial NCT03836105?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.